Innovations & Research

Learn how materials, such as plastic, are being developed from renewable resources like plants.

BIO supports all avenues of research to investigate therapies for debilitating diseases such as Parkinson's.

In this interview, BIO President and CEO Jim Greenwood explains the promise of stem cell research and why it is an important first step in bringing new therapies to patients.

Total job creation, accounting for economic multiplier effects, could reach 123,000 in 2012, 383,000 in 2016, and 807,000 by 2022.

December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.  
July 28 2011
BIO submitted testimony in support of USDA research funding to the House Agriculture Subcommittee on Rural Development, Research, Biotechnology, and Foreign Agriculture. Ag research programs within the USDA have sparked agricultural innovation and will help to solve the critical food and energy security challenges facing a rapidly growing global population.
January 11 2011
Public oral comments by David Edwards (BIO) to President's Council of Advisors on Science and Technology (PCAST) regarding the need to increase funding for agricultural research in research agencies and for extramural grants.
May 27 2009
The Biotechnology Industry Organization (BIO) thanks the National Institutes of Health (NIH) for the opportunity to submit comments on the draft guidelines for human stem cell research, published in the Federal Register on April 23, 2009...
June 6 2007
As President & CEO of the Biotechnology Industry Organization (BIO), I am writing to express BIO’s support for S. 5, the Stem Cell Research Enhancement Act...
March 25 2014
Principles reaffirm and broaden biotech industry’s commitment to transparency, advancing research
March 5 2014
Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 
July 10 2013
H.R. 2629 will cut compliance costs for innovative emerging biotech companies
April 8 2013
Strong Intellectual Property Protection Is Vital For The Life Sciences Industry.
July 20 2012
New bill will update SEC filing status classifications to ease costly regulatory burdens on small public companies